Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Investment firm Curreen Capital posted a 30.97% annual return for 2025, crediting its focus on undervalued, well-managed companies. The firm's latest investor letter highlights home service provider Frontdoor (FTDR) as a key holding, despite it not being among the most popular hedge fund picks.
Ryman Hospitality Properties has successfully expanded and extended its revolving credit facility to $850 million, providing the company with enhanced liquidity and revised covenants to navigate the evolving hospitality landscape and fund its long-term, experience-driven strategy.
Investment firm Giverny Capital has sold its position in auto-finance provider Credit Acceptance Corporation, citing a challenging market environment dominated by AI hype and large-cap tech outperformance. The move highlights a broader divergence between fundamental business performance and current investor sentiment.
A deep dive into Guardian Pharmacy Services (NYSE:GRDN) using a discounted cash flow model suggests its current share price is hovering close to its estimated intrinsic value. While the analysis provides a quantitative benchmark, investors are cautioned that valuation is just one piece of the puzzle in a complex and regulated healthcare sector.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
Shares of restaurant software leader Toast have tumbled over 37% in six months. While strong recurring revenue and solid growth forecasts provide a bullish case, concerns over customer acquisition costs paint a more complex picture for potential investors.
While many chase high-risk, loss-making stories, Tyler Technologies (TYL) stands out with consistent profitability and growth. We examine the key metrics and management alignment that make this software provider a stock worth watching.
A recent adjustment to Dexterra Group's price target by analysts, issued without detailed rationale, has stirred debate among market watchers. The move prompts a closer look at the underlying factors that may be influencing valuation models for the facilities management and workforce accommodation provider.
The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.
Satellite communications provider Viasat (VSAT) saw its shares hit a new 52-week peak of $46.49, capping a remarkable 12-month rally. The surge follows a significant price target upgrade from Morgan Stanley and the successful launch of a key global network for government clients.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
A final arbitration ruling in favor of Venture Global LNG against Spain's Repsol resolves a high-stakes contractual dispute, providing clarity on cash flows and bolstering confidence in the company's long-term project viability amid volatile energy markets.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
Marsh McLennan Agency unveils a group captive insurance solution designed specifically for senior living communities, aiming to provide stable liability coverage and risk management support in a challenging market.
A former Google employee has filed a formal complaint with the SEC, accusing the tech giant of breaching its own AI ethics principles by providing customer support to an Israeli defense contractor using AI to analyze drone footage, according to documents obtained by The Washington Post.
The diversified solutions provider faces analyst expectations of a nearly 30% year-over-year revenue drop when it reports Tuesday afternoon, following a mixed track record against Wall Street estimates.
